Pacira BioSciences, Inc. cotiza a 36.31 USD y tiene una capitalización bursátil de $1.4B. En los últimos 12 meses ha facturado $746M con un margen de flujo de caja libre del 18.8%. Cotiza a 8.1 veces su flujo de caja libre (P/FCF) y a un PER de 99.0. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management;…
| Periodo | 2026-11 | 2026-08 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.73 | $0.60 | $0.57 |
| Estimado | $0.73 | $0.65 | $0.56 | $0.90 |
| Sorpresa | — | +12.3% | +7.1% | -36.7% |
| Métrica | PCRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 79.4% | 57.0% | +22.4% |
| Operating Margin | 2.6% | -38.6% | +41.3% |
| Net Margin | 1.0% | -33.6% | +34.5% |
| FCF Margin | 18.8% | -13.9% | +32.7% |
| ROE | 1.0% | -40.4% | +41.4% |
| ROA | 0.6% | -32.0% | +32.6% |
| Current Ratio | 4.54 | 2.84 | +1.70 |
| Debt / Equity | 0.54 | 0.28 | +0.26 |